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Abstract
Objective—To estimate the risk of Parkinson's disease in individuals with mutations in the
Parkin gene.
Design—We assessed point mutations and exon deletions and duplications in the Parkin gene in
247 PD probands with age at onset !50 and 104 control probands enrolled in the Genetic
Epidemiology of PD study. For each first-degree relative, a consensus diagnosis of PD was
established. The probability that each relative carried a mutation was estimated from the proband's
Parkin carrier status using Mendelian principles and the relationship of the relative to the
proband .
Results—Parkin mutations were identified in 25 PD probands (10.1%), 72% of whom were
heterozygotes. One Parkin homozygote reported 2 siblings with PD. The cumulative incidence of
PD to age 65 in carrier relatives (age-specific penetrance) was estimated to be 7.0% (95% CI:
0.4-71.9%) compared to 1.7% (95% CI: 0.8-3.4%) in non-carrier relatives of cases (p=0.59) and
1.1% (95% CI: 0.3-3.4%), in relatives of controls ( compared to non-carriers p=0.52).
Conclusions—The cumulative risk of PD to age 65 in a non-carrier relative of a case with AAO
!50 is not significantly greater than the general population risk among controls. Age specific
penetrance among Parkin carriers, in particular heterozygotes, deserves further study.
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Introduction
Mutations in the Parkin gene (PARK2)1, 2 are associated primarily with early-onset
Parkinson's disease (EOPD), defined as age at onset (AAO) ranging from !45 to !553-7, but
have also been described in PD cases with an AAO over 70 years 7-10. In PD cases with
AAO ! 45 with a mode of inheritance consistent with autosomal recessive transmission, the
frequency of Parkin mutations may be as high as 49%3 while in cases without a family
history of PD the range is 15-18%.4, 6 AAO is inversely correlated with the frequency of
Parkin mutations in both familial3 and sporadic6 cases.
Several studies have compared the AAO of PD in heterozygous, compound heterozygous,
and homozygous Parkin mutation carriers 3-10 and found that heterozygous cases, both
familial and sporadic, have older AAO. Heterozygous Parkin mutation carriers are more
frequently reported among sporadic than familial cases7.
Information on the risk of PD in individuals who carry Parkin mutations in either the
homozygous, compound heterozygous, or heterozygous state (or penetrance) is essential for
genetic counseling. The penetrance of Parkin mutations has only been reported for isolated
families7. Most of the previous study designs sampled PD cases based on family history of
PD, which would bias penetrance estimates upwards11, 12. To obtain an unbiased estimate of
risk, a population-based random sample would be desirable, but Parkin mutations are so rare
in the population that such a sample would have to be extremely large to obtain sufficient
precision in penetrance estimates.
To obtain unbiased estimates of the risk of PD in Parkin carriers despite the low population
frequency of Parkin mutations 13, we used a kin-cohort study design11, 12 applied to
participants in the Genetic Epidemiology of Parkinson's Disease (GEPD) study14. The kin-
cohort design is highly efficient for estimating penetrance, because the relatives’ mutation
status is not required for the analyses, thus reducing costs for genetic analysis15.
Methods
Subjects
Details of the GEPD study have been previously described 14, 16, 17. Cases were ascertained
based on AAO of motor signs !50 (EOPD) or >50 (LOPD). In this study we included all
247 PD cases with AAO !50. All cases were recruited from the Center for Parkinson's
Disease and Other Movement Disorders at Columbia University (CPD), and EOPD cases
were oversampled14. One hundred and five controls were randomly selected from 412
controls in the GEPD study for complete sequencing of the Parkin gene.18 The majority of
the controls were recruited by random digit dialing, with frequency matching by age,
gender, ethnicity and area code/exchange. An additional sample of 40 controls of Hispanic
descent, 11 African American (AA) controls and 170 Caucasian controls participating in
GEPD were used to examine Parkin variants that have not been previously described. All
PD cases and control probands were seen in-person and underwent an identical evaluation14
that included a medical history, Unified Parkinson's Disease Rating Scale (UPDRS)19 and
videotape assessment.
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Diagnosis of PD in Relatives
Information on the family history of PD in first-degree relatives was obtained by
administering a reliable, validated interview to each case, control, and first-degree relative.
For relatives who were deceased or otherwise unavailable for interview, the history was
obtained by interviewing the most knowledgeable informant16. An algorithm was created to
generate a final diagnosis for PD in each first-degree relative based on the family history
interview and the direct interview with the relative. For relatives diagnosed with PD, a level
of certainty was assigned as definite, probable, possible, uncertain, and unlikely. For first-
degree relatives who met criteria for uncertain, possible, probable or definite PD, we tried to
obtain additional information in the form of an examination, medical records, or an
independent interview by a neurologist. A best estimate diagnosis of PD was assigned for
each relative 14. Family history information including age at onset of PD was available for
1330 relatives of 224 PD cases and 638 relatives of 103 controls included in the penetrance
analysis. The Institutional Review Board at the College of Physicians and Surgeons,
Columbia University approved this study.
Criteria for Inclusion of Mutation Carriers—All sequence variants identified in cases
and controls were genotyped in ethnically matched controls. Sequence variants observed in
controls but at a frequency of !1% were classified as rare variants. The remaining variants
were classified as mutations and included in the analysis based on three criteria: 1) The
mutation is absent in controls 2) The mutation is recurrent , has been reported in PD cases
(unrelated) in more than one study, or the mutation changes an amino acid that is
evolutionarily conserved and which is predicted to effect protein function 3) The mutation is
located in the coding region and predicted to change the amino acid sequence.
Molecular Genetic Analysis of Probands
Mutation screening was performed in 247 cases and 105 controls to detect point mutations
and exon deletions and duplications in the Parkin gene. In a previous study, we sequenced
all Parkin exons and screened for exon deletions and duplications by semi-quantitative
multiplex PCR in 101 cases and 105 controls18. One control was subsequently found to have
a putative splice variant IVS6-14 C>G, that has not been reported in cases or controls. We
consider this a rare variant and not a mutation and have excluded it from the analysis. In this
study we report data on an additional 146 PD cases from the GEPD study who were
screened for Parkin mutations by denaturing high performance liquid chromatography
(DHPLC) (WAVE Transgenomic), which has 100% sensitivity and specificity. Primers and
DHPLC conditions used for analysis of the Parkin gene have been described previously20.
Amplicons were either directly sequenced (n=126) or analyzed using a Parkin genotyping
array (n=20)21 in DNA samples with abnormal elution profiles. The genotyping array has
excellent sensitivity and specificity for detection of sequence variants when compared to the
gold standard of sequencing21. The primers used for PCR amplification of Parkin exons
1-12 and intron-exon boundaries and sequencing have been described previously22. Cycle
sequencing was performed on the purified PCR product as per the manufacturer's
instructions (BigDye, Applied Biosystems). Products were analyzed on an ABI3700 genetic
analyzer. Chromatograms were viewed using Sequencher (Genecodes) and sequence
variants determined. All sequence variants identified in cases and controls were confirmed
by analysis in a separate PCR followed by bi-directional sequencing. To identify genomic
deletions and exon rearrangements in Parkin, semi-quantitative multiplex PCR was
performed as previously described18.
In addition to screening for mutations in Parkin, we genotyped five LRRK2 mutations
(G2019S, L1114L, I1122V, R1441C and Y1699C) in 247 cases and 104 controls. Results of
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the analysis of LRRK2 in all participants in the GEPD study, including both early and late
onset PD cases, and all controls have been reported.23
Statistical methods
Demographic and clinical characteristics were compared between cases and controls and
between mutation carriers and non-carriers. Fisher's exact test for categorical characteristics
and Student's t-test for continuous characteristics were used to assess statistical significance.
The penetrance of Parkin mutations was estimated using the kin-cohort11 method. In this
method, the genotypes of the relatives are first estimated using Mendelian principles and the
relationship of the relatives to the proband. Then the observed disease occurrence in the
relatives is evaluated in relation to these estimated genotypes. This method assumes that,
although the PD case probands were sampled through their AAO, thereby increasing the
proportion of carriers among cases and their first-degree relatives, the relatives of these PD
cases are representative of randomly chosen individuals with certain genotypes. Hence
familial influences on the relatives’ PD risk other than the Parkin genotype are assumed to
be negligible.
First, we computed the probability that each relative carries a mutation. Second, we used the
kin-cohort method to estimate genotype-specific disease rates, using the consensus
diagnoses of PD in the first-degree relatives16, 17. Third, we used Kaplan-Meier survival
analysis to compute the cumulative risk of PD in the first-degree relatives of control
probands. Kaplan-Meier analysis cannot be directly applied to estimate genotype-specific
cumulative incidence in the relatives of cases because the carrier status in these relatives is
unknown; however the kin-cohort method allows calculation of cumulative incidence
through a method similar to Kaplan–Meier analysis. Confidence intervals for the penetrance
and the cumulative incidence were computed using log-log transformation to ensure the
lower limits of the confidence intervals were positive 24.
Results
Demographic and Clinical Characteristics of the Case and Control Probands
Demographic and clinical characteristics of the cases and controls are shown in Table 1. The
mean AAO of the 247 cases was 41.8 years (SD: 6.8), mean disease duration was 10.7 (SD:
7.6) years, and the total motor score (UPDRS Part III) was 20.3 (SD: 12.8). Nineteen (8.5%)
of the 224 cases on whom family history information was available had a diagnosis of PD in
a first-degree relative.
Frequency of Parkin Mutations in Cases and Controls
Twenty-five (10.1%) of the 247 cases had a Parkin mutation; five (20%) were homozygous,
two (8%) were compound heterozygotes and eighteen (72%) were heterozygous (Table 2).
Twenty two of the mutations have been previously described in other studies 2, 21, 22 Three
new mutations were identified that have not been previously published and were not
detected in any of our control samples (Iso298Leu, Asp18Asn, and Pro153Arg). Eleven
different point mutations (c.81G>T, Gly319Gly, Arg42Pro, Arg275Trp, Met192Leu,
Cys253Tyr, Asp280Asn, Iso298Leu, Arg366Gln, Asp18Asn, Pro153Arg) and four different
exon rearrangements were identified (Exon 5 del, Exon 3-4del, Exon 3 40bp del and Exon 2
del) (Table 2). Point mutations included nine missense mutations (Arg42Pro, Arg275Trp,
Met192Leu, Cys253Tyr, Asp280Asn, Iso298Leu, Arg366Gln, Asp18Asn, Pro153Arg), one
synonymous substitution (Gly319Gly), and a non-coding 5’UTR mutation (c.81G>T). Exon
deletions were found in four different exons (exons 2, 3, 4 and 5). 40 percent (10/25) of the
variants identified in cases were found in exons encoding functional domains including the
ubiquitin domain (Exon 2) and RING1 domain (Exon 7). Six cases carried the Exon 3 40bp
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deletion, five cases carried Arg275Trp and two carried Arg42Pro. We previously reported
that the synonymous substitution, Leu261Leu, is a variant rather than a disease associated
mutation and thus have not included carriers of Leu261Leu in our estimates23. Among the
25 carriers, three (12%) had AAO !20 (2/3 heterozygotes); four (16%) had AAO 21-30 (3/4
heterozygotes); six (24%) had AAO 31-40 (5/6 heterozgygotes); and twelve (48%) had
AAO 41-50 (8/12 heterozgyotes). Among all 247 EOPD case probands, carriers represented
75% (3/4) of those with AAO!20, 36% (4/11) of those with AAO 21-30, 8% (6/73) of those
with AAO 31-40, and 8% (12/159) of those with AAO 41-50.
Clinical Characteristics of Case Probands With and Without Parkin Mutations
Demographic and clinical features of the 25 mutation carriers and 222 non-carriers are
shown in Table 3. The AAO of PD was significantly younger in carriers (36.5 ± 10.3) than
in non-carriers (42.4 ± 6.1) (p=0.01), but did not differ between heterozygotes compared to
compound heterozygotes and homozygotes combined. Other comparisons of clinical
features were not significant.
The clinical characteristics of first-degree relatives stratified by the probands’ mutation
status are presented in Table 4. Information on the family history of PD in first-degree
relatives was available for 23/25 carriers and 201/218 non-carriers. One of 23 carrier
probands (4.4%) had a family history of PD. This proband is homozygous for an 40 bp
deletion in exon 3 and had two affected siblings (AAO 26, 30).
Penetrance Estimates of Parkin Mutations
The probability of a relative being a carrier, whether or not he/she was actually diagnosed
with PD, stratified by the proband's carrier status is presented in Table 5. In the calculation,
the population frequency of Parkin mutations, p, was assumed to be 0.03% {Lucking, 2000
#1168; Oliveira, 2003 #2;. We have run a sensitivity analysis by taking p to be 2.8% (the
upper limit of the 95% exact confidence interval of the mutation frequency estimated from
the controls) and the results did not change, suggesting that the estimates are robust to
misspecification to the population frequency of Parkin mutations.
The expected genotype distribution in the relatives and the prevalence of a history of PD in
relatives predicted to be carriers or noncarriers are shown in Table 6. To obtain these
prevalence estimates, we first computed the probability that each of the relatives was a
carrier based on the observed carrier status in the probands (see Table 1) and then combined
the information on the predicted genotypes in the relatives with the observed PD diagnoses
in the relatives. There were 93 relatives expected to be carriers (homozygotes or
heterozygotes), among whom 2 had PD (Table 6). Therefore, the prevalence of a history of
PD in carrier relatives was estimated at 2/93 [2.2% (CI: 0.3%, 7.6%)]. Among relatives
expected to be noncarriers (N=1237), 19 had PD (Table 6); thus the prevalence of a history
of PD in noncarrier relatives was estimated as 1.7% (0.9-2.4%). These two prevalence
estimates did not differ significantly.
The cumulative incidence of PD in 1330 relatives of case probands (without regard to carrier
status) was estimated to be 1.7% (95% CI: 0.9-3.3%) to age 65, and 5.9% (95% CI:
3.7-9.3%) to age 80. Estimates of the cumulative risk of PD in Parkin carriers and non-
carriers and the cumulative risk of PD in 647 relatives of controls are presented in table 7.
Among relatives expected to be carriers, the cumulative incidence of PD was 7.0% to age 65
and remained so up to age 80. Among relatives expected to be noncarriers, the cumulative
incidence was 1.7% to age 65 and 6.1% to age 80. The ratio of the cumulative incidence to
age 80 for carriers versus non-carriers was 1.1 (95% CI: 0.07-18.8). Estimates of risk in
carriers and noncarriers did not differ significantly with our sample size. The cumulative
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incidence in relatives of controls was similar to that in relatives expected to be noncarriers
(1.1% to age 65 and 4.1% to age 80).
We have reported that LRRK2 mutations may be responsible for familial aggregation in
both EOPD and LOPD in the GEPD study{Clark, 2006 #12300}. To separate out the effect
of the LRRK2 G2019S mutation (the only observed LRRK2 mutation in the cases), we
repeated our analyses using 214 case probands who did not carry a LRRK2 mutation.
However, we can not we can not exclude the possibility that they carry ‘other’ mutations in
the LRRK2 gene as we did not completely sequence the LRRK2 gene but only genotyped 5
previously reported LRRK2 mutations. There were 1274 relatives included in the analysis.
Since these relatives were family members of probands who did not carry any of the five
previously identified LRRK2 mutations, it is unlikely they carry any of these mutations. The
cumulative incidence to age 80 for relatives expected to be non-carriers of either LRRK2
mutations or Parkin mutations was 5.9%, compared to 6.1% for relatives expected to be
noncarriers of Parkin mutations. The cumulative incidence of PD to age 80 in non-Parkin,
non-LRRK2 carrier relatives was not significantly different from controls.
Discussion
Using the kin-cohort method, we have shown that the cumulative risk to age 65 in a relative
of an EOPD case who is not estimated to carry a Parkin mutation is not significantly greater
than the general population risk among controls. We estimated a cumulative risk of PD in
carriers of Parkin mutations (age-specific penetrance) of 7.0% (95% CI: 0.4-71.9%) up to
age 80. We were unable to examine risk of PD among heterozygotes separately. Parkin
heterozgyosity may not be sufficient for the development of PD. A recent paper suggested
that Parkin variants were equally common in cases and controls in predominantly non-
coding regions25.
The sampling scheme of our study, in which probands were ascertained without regard to
their family history of PD, differs markedly from that in other studies that included only
families with multiple affected individuals. As noted in the context of estimating the
penetrance of mutations in BRCA1 and BRCA2, penetrance estimates are inflated when
based on samples selected though family history 12, 15, and hence we believe our estimates
are more representative of those in the general population than are those derived from
familial samples. While the confidence intervals are extremely wide, the observed low
frequency of PD in first-degree relatives of Parkin mutation carriers, 72% of whom are
heterozygotes, may be a reflection of the low penetrance in carriers.
The frequency of Parkin mutations was 10.1% (95% CI: 8.0-16.4%) in 247 cases with AAO
! 50, which is within the range of other series with primarily sporadic cases (15-18%)6, or
population-based series (9%)26. The mean AAO of our case sample was 41.6 years, and
48% of the cases had AAO between 40 and 50. The frequency of Parkin mutations has been
reported to decrease with increasing age-at-onset3, 6. While the age-specific frequencies of
carriers are similar to other reported series6, the high percentage of older cases in this study
may explain why we report a frequency at the lower end of the spectrum.
Limitations
There are three important limitations in this study. Most importantly, the number of relatives
of probands who are estimated to carry Parkin mutations is limited, which results in
cumulative risk estimates with wide confidence intervals. We have limited our study to only
those who participated in the GEPD study for whom we have accurate information on vital
status, a necessary criterion for the kin-cohort method. In addition, only 105 controls were
completely sequenced for the Parkin gene, which may explain our inability to detect
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differences between relatives of PD probands and relatives of control probands. The sample
size required for a typical kin-cohort study is usually large, due to the low population
prevalence of the mutation being studied. Second, the diagnosis in the relatives was a best
estimate diagnosis. We have previously reported high sensitivity (95.5%) and specificity
(96.2%) of our family history questionnaire based on examination of 141 relatives. Third,
we did not have actual genotype data on relatives. We used the kin-cohort method to
estimate penetrance in the absence of these data.
Some relatives may have been too young to manifest PD. Our sampling plan was to include
all probands with AAO !50 regardless of their family history of PD and AAO in the
relatives. The relatives of these probands are likely to be younger than the relatives of
randomly selected PD patients. In a study of affected sibling pairs, the mean AAO of
heterozygous Parkin carriers was reported to be 49.6.10 Forty-nine percent of the relatives in
our sample were younger than 49.6 (Table 4). Our estimates of the prevalence of a history of
PD in the relatives do not account for this young age distribution, and thus underestimate
prevalence of PD according to Parkin genotype in the general population. We accounted for
the younger age distribution by computing age-specific cumulative incidence of PD
according to genotype.
One assumption required for the kin-cohort analyses to be valid is that risk of PD in relatives
within the same family is independent, given the proband's Parkin genotype. The presence
of other genetic and environmental risk factors that aggregate in the families may violate
this assumption and bias the penetrance estimation15, 27. Due to the possibility of additional
unspecified familial risk factors in the relatives of early-onset PD probands, penetrance
estimates obtained from our sample can be applied to the population of relatives of the early-
onset PD probands but not to the entire population.
We are currently recruiting a larger multi-center sample of early-onset cases and examining
and obtaining DNA in relatives of carrier probands. We hope to use this new sample to
refine our estimates of penetrance in heterozygous, homozygous, and compound
heterozygous carriers.
Acknowledgments
This study was funded by NIH NS36630, RR00645 (KM) and the Parkinson's Disease Foundation (KM and LNC).
The authors thank Dr. Paul Greene for his participation.
References
1. Kitada T, Asakawa S, Hattori N, et al. Mutations in the parkin gene cause autosomal recessive
juvenile parkinsonism. Nature 1998;392:605–8. [PubMed: 9560156]
2. Hedrich K, Eskelson C, Wilmot B, et al. Distribution, type, and origin of Parkin mutations: Review
and case studies. Mov Disord 2004;19:1146–57. [PubMed: 15390068]
3. Lucking CB, Durr A, Bonifati V, et al. Association between early-onset Parkinson's disease and
mutations in the parkin gene. French Parkinson's Disease Genetics Study Group. N Engl J Med
2000;342:1560–7. [PubMed: 10824074]
4. Hedrich K, Marder K, Harris J, et al. Evaluation of 50 probands with early-onset Parkinson's disease
for Parkin mutations. Neurology 2002;58:1239–46. [PubMed: 11971093]
5. Abbas N, Lucking CB, Ricard S, et al. A wide variety of mutations in the parkin gene are
responsible for autosomal recessive parkinsonism in Europe. French Parkinson's Disease Genetics
Study Group and the European Consortium on Genetic Susceptibility in Parkinson's Disease. Hum
Mol Genet 1999;8:567–74. [PubMed: 10072423]
6. Periquet M, Latouche M, Lohmann E, et al. Parkin mutations are frequent in patients with isolated
early-onset parkinsonism. Brain 2003;126:1271–8. [PubMed: 12764050]
Wang et al. Page 7






















7. Lohmann E, Periquet M, Bonifati V, et al. How much phenotypic variation can be attributed to
parkin genotype? Ann Neurol 2003;54:176–85. [PubMed: 12891670]
8. Foroud T, Uniacke SK, Liu L, et al. Heterozygosity for a mutation in the parkin gene leads to later
onset Parkinson disease. Neurology 2003;60:796–801. [PubMed: 12629236]
9. Oliveira SA, Scott WK, Martin ER, et al. Parkin mutations and susceptibility alleles in late-onset
Parkinson's disease. Ann Neurol 2003;53:624–9. [PubMed: 12730996]
10. Sun M, Latourelle JC, Wooten GF, et al. Influence of heterozygosity for parkin mutation on onset
age in familial Parkinson disease: the GenePD study. Arch Neurol 2006;63:826–32. [PubMed:
16769863]
11. Wacholder S, Hartge P, Struewing JP, et al. The kin-cohort study for estimating penetrance. Am J
Epidemiol 1998;148:623–30. [PubMed: 9778168]
12. Struewing JP, Hartge P, Wacholder S, et al. The risk of cancer associated with specific mutations
of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997;336:1401–8. [PubMed:
9145676]
13. Dekker MC, Bonifati V, Van Duijn CM. Parkinson's disease: piecing together a genetic jigsaw.
Brain. 2003
14. Marder K, Levy G, Louis ED, et al. Familial aggregation of early- and late-onset Parkinson's
disease. Ann Neurol 2003;54:507–13. [PubMed: 14520664]
15. Gail MH, Pee D, Benichou J, Carroll R. Designing studies to estimate the penetrance of an
identified autosomal dominant mutation: cohort, case-control, and genotyped-proband designs.
Genet Epidemiol 1999;16:15–39. [PubMed: 9915565]
16. Marder K, Levy G, Louis ED, et al. Accuracy of family history data on Parkinson's disease.
Neurology 2003;61:18–23. [PubMed: 12847150]
17. Levy G, Louis ED, Mejia-Santana H, et al. Lack of familial aggregation of Parkinson disease and
Alzheimer disease. Arch Neurol 2004;61:1033–9. [PubMed: 15262733]
18. Clark LN, Afridi S, Karlins E, et al. Case-control study of the parkin gene in early-onset Parkinson
disease. Arch Neurol 2006;63:548–52. [PubMed: 16606767]
19. Fahn S, Marsden CD, Calne D. Recent Developments in Parkinson's Disease. Florham Park, N. J.
Macmillan Healthcare Information. 1987
20. Pigullo S, De Luca A, Barone P, et al. Mutational analysis of parkin gene by denaturing high-
performance liquid chromatography (DHPLC) in essential tremor. Parkinsonism Relat Disord
2004;10:357–62. [PubMed: 15261877]
21. Clark LN, Haamer E, Mejia-Santana H, et al. Construction and validation of a Parkinson's disease
mutation genotyping array for the Parkin gene. Mov Disord 2007;22:932–7. [PubMed: 17415800]
22. West A, Periquet M, Lincoln S, et al. Complex relationship between Parkin mutations and
Parkinson disease. Am J Med Genet 2002;114:584–91. [PubMed: 12116199]
23. Clark LN, Wang Y, Karlins E, et al. Frequency of LRRK2 mutations in early- and late-onset
Parkinson disease. Neurology 2006;67:1786–91. [PubMed: 17050822]
24. Kalbfleisch JDaP, RL. The Statistical Analysis of Failure Time Data. John Wiley & Sons, Inc.;
New York: 1980.
25. Kay DM, Moran D, Moses L, et al. Heterozygous parkin point mutations are as common in control
subjects as in Parkinson's patients. Ann Neurol 2007;61:47–54. [PubMed: 17187375]
26. Kann M, Jacobs H, Mohrmann K, et al. Role of parkin mutations in 111 community-based patients
with early-onset parkinsonism. Ann Neurol 2002;51:621–5. [PubMed: 12112109]
27. Begg CB. On the use of familial aggregation in population-based case probands for calculating
penetrance. J Natl Cancer Inst 2002;94:1221–6. [PubMed: 12189225]
Wang et al. Page 8











































Wang et al. Page 9
Table 1
Demographic Characteristics of Case and Control Probands
Total (n=351) Cases (n=247) Controls (n=104) Significance Cases vs. Controls
% male (n) 59.7 (209) 61.1 (151) 55.8 (58) 0.40
Age (years) (sd) 54.9 (10.2) 52.5 (9.0) 60.8 (10.5) <0.001
% White (n) 84.3 (296) 81.0 (200) 92.3 (96)
% African-American (n) 2.3 (8) 2.0 (5) 2.9 (3)
% Hispanic (n) 8.0 (28) 10.1 (25) 2.9 (3)
% Other (n) 5.4 (19) 6.9 (17) 1.9 (2) 0.02
Years Education (sd) 15.5 (3.2) 15.5 (3.3) 15.5 (2.9) 0.97
% with Parkin variants (n) 7.1 (25) 10.1 (25) 0.0 (0) <0.001
% with family history of PD* (n) 7.7 (25) 8.5 (19/224) 5.8 (6/103) 0.50
*
Family history was available for 328 probands (224 cases and 103 controls)
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Table 3
Characteristics of Case Probands With and Without Parkin Mutations
Mutation (n=25) No mutation (n=222) p value
Current age (sd) 47.2 (9.9) 53.1 (8.7) 0.008
Age onset (sd) 36.5 (10.3) 42.4 (6.1) 0.01
% male (n) 40.0 (10) 63.5 (141) 0.03
% Ethnicity: White (n) 64.0 (16) 82.3 (184)
African-American (n) 0.0 (0) 2.3 (5)
Hispanic (n) 28.0 (7) 8.1 (18) 0.03
Other (n) 8.0 (2) 6.8 (15)
Years education (sd) 14.1 (3.8) 15.6 (3.3) 0.06
Duration PD (yrs)(sd) 10.6 (7.5) 10.7 (7.7) 0.96
Total motor score (UPDRS III)(sd) 22.1 (15.8) 20.1 (12.2) 0.57
Total modified mini mental state (mMMS) (sd) 52.3 (5.3) 53.7 (4.6) 0.24
% Family history PD in first-degree relative* 4.4 (1/23) 8.9 (18/201) 0.72
% Bradykinesia 88.0 (22) 82.9 (184) 0.78
% Rest tremor 80.0 (20) 78.2 (172/220) 1.00
% Rigidity 96.0 (24) 98.7 (219) 0.35
% Postural instability 44.0 (11) 45.0 (99/220) 1.00
% Asymmetry 96.0 (24) 88.5 (192/217) 0.49
% on L dopa 70.8 (17/24) 70.2 (153/218) 1.00
% Improve L dopa 95.0 (19/20) 97.4 (150/154) 0.46
%On-off 51.7 (15) 53.6 (113/211) 1.00
Hoehn and Yahr (sd) 2.3 (0.9) 2.1 (0.9) 0.32
% First symptom†: rest tremor (n) 44.0 (11) 48.9 (108) 0.68
% First symptom: gait (n) 0.0 4.5 (10) 0.60
% First symptom: rigidity (n) 8.0 (2) 9.5 (21) 1.00
% First symptom: bradykinesia (n) 4.0 (1) 4.1 (9) 1.00
% First symptom: motor (n) 4.0 (1) 1.8 (4) 0.42
% First symptom: poor balance (n) 4.0 (1) 0.5 (1) 0.19
% First symptom: pain (n) 8.0 (2) 1.8 (4) 0.12
*
Family history was available for 224 case probands.
†
First symptom information was available for 221 out of 222 non-carriers.
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Table 5
Probability of a relative being a carrier stratified by the proband's mutation status*
Relatives of homozygous or compound heterozygous probands
Probability of the relative being a
homozygous carrier
Probability of the relative being a
heterozygous carrier
Probability of the relative being a
non-carrier
Parent P 1- p 0
Sibling ¼*(p2-2 p+1) 1/2*(- p2+1) 1/4*(1-p)2
Offspring P 1- p 0
Relatives of heterozygous probands
Probability of the relative being a
homozygous carrier
Probability of the relative being a
heterozygous carrier
Probability of the relative being a non-
carrier
Parent l/2*p 1/2 1/2*(1-p)
Sibling 1/4*(p2 +p) 1/2*(- p2+ p+1) 1/4*(p2-3p +2)
Offspring 1/2*p 1/2 1/2*(1-p)
Relatives of non-carrier probands
Probability of the relative being a
homozygous carrier
Probability of the relative being a
heterozygous carrier
Probability of the relative being a non-
carrier
Parent 0 p 1-p
Sibling 1/4*p2 1/2(-p2+2p) 1/4*(p2-4p+4)
Offspring 0 p 1-p
*
p is the population frequency of the mutation.
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Table7
Estimated cumulative incidence of PD in Parkin carrier relatives, non-carrier relatives, and relatives of
controls
Age Parkin Carrier (Homozygotes and heterozygotes)
Relatives (95% CI)











(0.4,71.9%) (0.1, 1.0%) (0.03-1.7%)
55
7.0% 0.4 0.2%
(0.4,71.9%) (0.1, 1.4%) (0.03, 1.7%)
60
7.0% 1.1 0.6%
(0.4,71.9%) (0.5, 2.5%) (0.1, 2.5%)
65
7.0% 1.7% 1.1%
(0.4,71.9%) (0.8, 3.4%) (0.3, 3.4%)
70
7.0% 3.3% 1.1%
(0.4,71.9%) (1.9, 5.7%) (0.3, 3.4%)
75
7.0% 4.6% 2.8%
(0.4,71.9%) (2.7, 7.5%) (1.1, 7.2%)
80
7.0% 6.1% 4.1%
(0.4,71.9%) (3.8, 9.8%) (1.7, 9.8%)
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